| Not Yet Recruiting | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) NCT07206849 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas NCT06465199 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Recruiting | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion NCT06333899 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Recruiting | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age NCT05956821 | University of Miami | Phase 1 / Phase 2 |
| Recruiting | Atovaquone Combined With Radiation in Children With Malignant Brain Tumors NCT06624371 | Emory University | Phase 1 |
| Recruiting | Study of Olutasidenib and Temozolomide in HGG NCT06161974 | Rigel Pharmaceuticals | Phase 2 |
| Recruiting | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant NCT05843253 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Targeted Pediatric High-Grade Glioma Therapy NCT05839379 | Nationwide Children's Hospital | — |
| Recruiting | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medullobla NCT05096481 | Nationwide Children's Hospital | Phase 2 |
| Recruiting | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG NCT06221553 | Chulalongkorn University | Phase 1 |
| Recruiting | GD2-CAR T Cells for Pediatric Brain Tumours NCT05298995 | Bambino Gesù Hospital and Research Institute | Phase 1 |
| Not Yet Recruiting | RE-irradiation of Diffuse MIdline Glioma paTients NCT06093165 | Rigshospitalet, Denmark | N/A |
| Recruiting | FUS Etoposide for DMG NCT05762419 | Columbia University | Phase 1 |
| Active Not Recruiting | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Di NCT05768880 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma NCT05717712 | Capital Medical University | Phase 1 |
| Recruiting | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma NCT05717699 | Capital Medical University | Phase 1 |
| Recruiting | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 NCT05476939 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 |
| Suspended | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG NCT05123534 | SonALAsense, Inc. | Phase 2 |
| Active Not Recruiting | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma an NCT04978727 | Children's Oncology Group | Phase 1 |
| Recruiting | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG NCT04943848 | Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 |
| Recruiting | Combination Therapy for the Treatment of Diffuse Midline Gliomas NCT05009992 | University of California, San Francisco | Phase 2 |
| Active Not Recruiting | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy NCT04837547 | University of Florida | Phase 1 |
| Active Not Recruiting | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Ponti NCT04911621 | University Hospital, Antwerp | Phase 1 / Phase 2 |
| Terminated | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glio NCT04804709 | Columbia University | Phase 1 |
| Terminated | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline NCT04771897 | Bexion Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine NCT04758533 | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Phase 1 / Phase 2 |
| Recruiting | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion NCT04655404 | Nationwide Children's Hospital | EARLY_Phase 1 |
| Unknown | Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma i NCT04532229 | Biotech Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma NCT04749641 | Yang Zhang | Phase 1 |
| Terminated | Phase I Study of Marizomib + Panobinostat for Children With DIPG NCT04341311 | Dana-Farber Cancer Institute | Phase 1 |
| Terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. NCT04239092 | Actuate Therapeutics Inc. | Phase 1 |
| Completed | CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas NCT04264143 | Luca Szalontay | Phase 1 |
| Recruiting | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) NCT04099797 | Baylor College of Medicine | Phase 1 |
| Recruiting | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Mid NCT04185038 | Seattle Children's Hospital | Phase 1 |
| Withdrawn | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma NCT04051047 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG NCT04049669 | Theodore S. Johnson | Phase 2 |
| Withdrawn | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas NCT03632317 | University of Michigan Rogel Cancer Center | Phase 2 |
| Active Not Recruiting | Fimepinostat in Treating Brain Tumors in Children and Young Adults NCT03893487 | Sabine Mueller, MD, PhD | EARLY_Phase 1 |
| Active Not Recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 | Pfizer | Phase 2 |
| Terminated | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Saf NCT03690869 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Gl NCT03605550 | Nationwide Children's Hospital | Phase 1 |
| Unknown | International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) NCT03243461 | University of Göttingen | Phase 3 |
| Completed | MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine NCT03566199 | Sabine Mueller, MD, PhD | Phase 1 / Phase 2 |
| Terminated | ONC201 in Pediatric H3 K27M Gliomas NCT03416530 | Jazz Pharmaceuticals | Phase 1 |
| Completed | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied NCT03355794 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Completed | CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glio NCT03086616 | Sabine Mueller, MD, PhD | Phase 1 |
| Terminated | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG NCT03330197 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With NCT03033992 | Children's Oncology Group | N/A |
| Completed | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas NCT02960230 | Sabine Mueller, MD, PhD | Phase 1 / Phase 2 |
| Completed | Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma NCT02992015 | University of Colorado, Denver | EARLY_Phase 1 |
| Unknown | Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines NCT02840123 | Fundació Sant Joan de Déu | Phase 1 |
| Suspended | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) NCT02742883 | Burzynski Research Institute | Phase 2 |
| Completed | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas NCT02750891 | Sumitomo Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy NCT02607124 | Children's Hospital Medical Center, Cincinnati | Phase 1 / Phase 2 |
| Completed | Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors NCT02644460 | Emory University | Phase 1 |
| Unknown | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses NCT03620032 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnose NCT02420613 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primar NCT02502708 | NewLink Genetics Corporation | Phase 1 |
| Completed | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or R NCT02444546 | Mayo Clinic | Phase 1 |
| Unknown | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication NCT02233049 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Completed | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas NCT01837862 | Julie Krystal | Phase 1 / Phase 2 |
| Completed | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gl NCT01922076 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Unde NCT01884740 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Completed | Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine G NCT01644773 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma NCT01400672 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository NCT03101813 | Children's Hospital Medical Center, Cincinnati | — |
| Terminated | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) NCT01182350 | Karen D. Wright MD | Phase 2 |
| Completed | PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Gr NCT01393912 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas NCT01222754 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma NCT01165333 | Centre Oscar Lambret | Phase 1 |
| Completed | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients NCT01189266 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma NCT01106794 | Children's National Research Institute | — |
| Completed | Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) NCT00996723 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Gli NCT00879437 | Baylor College of Medicine | Phase 2 |
| Completed | A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Ponti NCT00890786 | Children's Hospital Medical Center, Cincinnati | EARLY_Phase 1 |
| Completed | Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors NCT01445288 | National Cancer Institute (NCI) | — |
| Completed | A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Glio NCT00036569 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered NCT05518838 | Oblato, Inc. | — |